Synchron Acquandas Share Acquisition To Increase Brain Implant Production

JAKARTA - The New York-based Synchron company announced on Thursday February 1, that it has acquired equity stocks in medical component maker Acquandas, in a bid to improve their brain implant manufacturing surgery.

Synchron, which is more advanced in the development of brain implants than Elon Musk's Neuralink, did not disclose the magnitude of the shares they acquired or the financial details of the deal.

The company launched a second trial of their brain implantation devices in the US early last year, by registering patients suffering from severe paralysis due to amyotrophic lateral sclerosis (ALS), stroke, spinal injury, or multiple sclerosis.

Like Neuralink, Synchron aims to help patients with severe paralysis control digital devices. They received human testing approval from the US FDA in July 2021, five years after submitting an application.